Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Google Secures Pentagon AI Deal for Classified Projects 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
CAMBRIDGE, Mass., April 26, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Deutsche Bank 42nd Annual Health Care Conference. The presentation is scheduled for Wednesday, May 3rd at 10:00 a.m. ET.
A webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
